Cures matter, implementation counts too, aim high

James Burrus/NIST

Biomedical engineer Jenni Popp with NISTs prototype bioreactor for tissue engineering February 29, 2012.

Article Highlights

  • In our efforts to improve American medicine, we shouldn’t scale back on our fundamental ambitions. @DShaywitz.

    Tweet This

  • Even as we try to use available resources effectively, it’s key to develop & offer novel treatments that may work better.

    Tweet This

  • Bottom line: Biomedical science is difficult, fragile and essential. @DShaywitz

    Tweet This

In the online edition of today's Atlantic, I share a piece that distills several topics familiar to readers of this column.  I write that in our efforts to improve American medicine, we shouldn't scale back on our fundamental ambitions - specifically, our investment in high-tech medical science, and our belief that each patient deserves the best care possible.

I argue that it's incredibly important to ensure technological advances are accessible to patients, and actually benefit them; yet, in attempting to effect a more equitable distribution of health, let's be careful not to reduce either our drive or ability to maximize individual health. 

Phrased differently: even as we strive to use available resources as effectively as possible, we must continue to develop and offer patients novel treatments that might work even better.

Most importantly, we must ensure physician remain advocates for the individual patients in their care, and not ask doctors to balance care of an individual patient with a broader commitment to preserving resources for society.  I don't want my doctor to recommend unnecessary or unhelpful treatments, and I certainly wouldn't want to stay in any hospital for one nanosecond longer than medically necessary - yet I also want to be positively sure that my doctor's recommendations are based on an absolute commitment to optimize my health, and not on some gauzy ethical balancing act he or she is trying to achieve.  (See here, and links therein, for more complete discussion.)

In the Atlantic piece, I also discuss the increasing concern that modern high-tech medicine has overpromised and underdelivered.  While I'm proud of the many achievements of biomedical science, it's true that we've come up short in a number of areas - neurodegenerative disease and most cancers come immediately to mind.  Our scientific foundation is considerably more fragile than many appreciate (a fact definitely not lost on most biotech investors these days), and industry plays a vital role in pressure-testing this knowledge, unfortunately discovering in the process just how shaky it is.

Consequently, while it's fashionable to critique the business-oriented executives who run most biopharmaceutical companies - and I certainly have - it's also likely the industry owes its survival not only to the  valiant effort of scientists, but also to the executives in suits who've found a way to manage through the frequent productivity droughts, usually through shrewd business acumen (and occasionally, as recent scandals suggest, through unfortunate and obviously unacceptable means).

Bottom line: biomedical science is difficult, fragile, and essential - qualities that map directly to the current state and esteem of the biopharmaceutical industry.   It's also critically important to figure out how to best use the technologies we already have, and to significantly improve care delivery - a vital area of medical research that has historically suffered from significant underinvestment.  Our key challenge is ensuring that in our increasingly deliberate efforts to manage and improve the health of society as a whole, we not lose focus on doing our utmost to improve the present and future health of the individual patients in our trust and care.

Final note: CATCH (the Center for Assessment Technology and Continuous Health), the new (non-profit) Boston-based innovation initiative I recently co-founded with MGH Chief-of-Medicine Dennis Ausiello (who will lead the effort) and several others, seeks precisely this balance between potential and attained health.  The idea is that improved real-world measurement of people and patients can improve care delivery and implementation in the short-term, and lead to fundamental advances and novel scientific insights down the road (see here, here, and here.)


Also Visit
AEIdeas Blog The American Magazine
About the Author


  • Dr. Shaywitz trained in internal medicine and endocrinology at MGH, and conducted his post-doctoral research in the Melton lab at Harvard. He gained experience in early clinical drug development in the Department of Experimental Medicine at Merck, then joined the Boston Consulting Group’s Healthcare and Corporate Development practices, where he focused on strategy and organizational design. He is currently Director of Strategic and Commercial Planning at Theravance, a publicly-held drug development company in South San Francisco. He recently wrote Tech Tonics: Can Passionate Entreprenuers Heal Healthcare With Technology? 

  • Email:

What's new on AEI

image Getting it right: US national security policy and al Qaeda since 2011
image Net neutrality rundown: What the NPRM means for you
image The Schuette decision
image Snatching failure from victory in Afghanistan
AEI on Facebook
Events Calendar
  • 21
  • 22
  • 23
  • 24
  • 25
Wednesday, April 23, 2014 | 12:00 p.m. – 1:30 p.m.
Graduation day: How dads’ involvement impacts higher education success

Join a diverse group of panelists — including sociologists, education experts, and students — for a discussion of how public policy and culture can help families lay a firmer foundation for their children’s educational success, and of how the effects of paternal involvement vary by socioeconomic background.

Thursday, April 24, 2014 | 12:00 p.m. – 1:30 p.m.
Getting it right: A better strategy to defeat al Qaeda

This event will coincide with the release of a new report by AEI’s Mary Habeck, which analyzes why current national security policy is failing to stop the advancement of al Qaeda and its affiliates and what the US can do to develop a successful strategy to defeat this enemy.

Event Registration is Closed
Friday, April 25, 2014 | 9:15 a.m. – 1:15 p.m.
Obamacare’s rocky start and uncertain future

During this event, experts with many different views on the ACA will offer their predictions for the future.   

Event Registration is Closed
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.